UNICEF and WHO Launch Global Plan Against Pneumonia
The World Health Organization (WHO) and UNICEF are kicking off a comprehensive plan to fight the world’s leading child killer.
News
Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
Unilife: Medical Device Innovator Creating Jobs in PA
Unilife Medical Solutions is an emerging medical device manufacturer with business segments that include pre-filled syringes for pharmaceutical companies to deliver injectable medications, sharps safety devices for healthcare facilities, and contract manufacturing of medical devices.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
OneMedPlace and OneMedForum Enter a Strategic Partnership with MarketWire
OneMedPlace has entered into a partnership with Marketwire, a full-service newswire and communications workflow solutions provider for public relations, investor relations and marketing communications professionals, to accomplish the company’s media outreach goals.
Cohera Receives Approval for Surgical Adhesive Trial
Pittsburgh-based Cohera Medical has received approval to begin clinical trials on its TissuGlu surgical adhesive in Europe.
Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
Zogenix, Astellas Announce Positive Data for Unique Migraine Therapy
Zogenix, a pharmaceutical company specializing in the treatment of chronic pain, and Astellas Pharma have announced positive clinical trial data from two studies of their needle-free migraine treatment system.
Osteologix to Continue Development of Osteoporosis Drug
Osteologix is positioning NB S101 as an alternative to traditional osteoporosis treatments.